{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:24:26Z","timestamp":1769617466191,"version":"3.49.0"},"reference-count":0,"publisher":"AME Publishing Company","issue":"1","content-domain":{"domain":["amegroups.com"],"crossmark-restriction":false},"short-container-title":["Transl Androl Urol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.21037\/tau-2025-703","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:44:06Z","timestamp":1768981446000},"page":"7-7","update-policy":"https:\/\/doi.org\/10.21037\/ame_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial"],"prefix":"10.21037","volume":"15","author":[{"given":"Yasutaka","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8611","published-online":{"date-parts":[[2026,1]]},"container-title":["Translational Andrology and Urology"],"original-title":[],"link":[{"URL":"https:\/\/tau.amegroups.com\/article\/download\/148285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:51:48Z","timestamp":1769568708000},"score":1,"resource":{"primary":{"URL":"https:\/\/tau.amegroups.com\/article\/view\/148285\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]},"published-print":{"date-parts":[[2026,1]]}},"URL":"https:\/\/doi.org\/10.21037\/tau-2025-703","relation":{},"ISSN":["2223-4683","2223-4691"],"issn-type":[{"value":"2223-4683","type":"print"},{"value":"2223-4691","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}